Concurrent inhibition of PI3-Kinase and mTOR induces cell death in diffuse large B cell lymphomas, a mechanism involving down regulation of Mcl-1

Cancer Letters

Volumn 339, Issue 2, 2013, Pages 288-297

  Zang, Chuanbing ^a   Eucker, Jan ^a   Liu, Hongyu ^a   Müller, Anja ^a   Possinger, Kurt ^a   Scholz, Christian Wilfried ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

ABC; DLBCL; GCB; NVP BEZ235; PI3K Akt mTOR

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; BUPARLISIB; EVEROLIMUS; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN MCL 1;

ARTICLE; B LYMPHOCYTE ACTIVATION; CELL DEATH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; GERMINAL CENTER; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

ABC; DLBCL; GCB; NVP-BEZ235; PI3K/AKT/MTOR;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMIDAZOLES; LYMPHOMA, LARGE B-CELL, DIFFUSE; NF-KAPPA B; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOPROTEINS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; PROTO-ONCOGENE PROTEINS C-PIM-1; QUINOLINES; RIBOSOMAL PROTEIN S6 KINASES, 70-KDA; RNA INTERFERENCE; SIGNAL TRANSDUCTION; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EUKARYOTA;

EID: 84883789103     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.11.013     Document Type: Article

References (44)

1. Alizadeh A.A., Eisen M.B., Davis R.E., Ma C., Lossos I.S., Rosenwald A., Boldrick J.C., Sabet H., Tran T., Yu X., Powell J.I., Yang L., Marti G.E., Moore T., Hudson J., Lu L., Lewis D.B., Tibshirani R., Sherlock G., Chan W.C., Greiner T.C., Weisenburger D.D., Armitage J.O., Warnke R., Levy R., Wilson W., Grever M.R., Byrd J.C., Botstein D., Brown P.O., Staudt L.M. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503-511.
2. Savage K.J., Al-Rajhi N., Voss N., Paltiel C., Klasa R., Gascoyne R.D., Connors J.M. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience. Ann. Oncol. 2006, 17:123-130.
3. Lenz G., Staudt L.M. Aggressive lymphomas. N. Engl. J. Med. 2010, 362:1417-1429.
4. Zhao M.Y., Auerbach A., D'Costa A.M., Rapoport A.P., Burger A.M., Sausville E.A., Stass S.A., Jiang F., Sands A.M., Aguilera N., Zhao X.F. Phospho-p70S6K/p85S6K and cdc2/cdk1 are novel targets for diffuse large B-cell lymphoma combination therapy. Clin. Cancer Res. 2009, 15:1708-1720.
5. Wanner K., Hipp S., Oelsner M., Ringshausen I., Bogner C., Peschel C., Decker T. Mammalian target of rapamycin inhibition induces cell cycle arrest in diffuse large B cell lymphoma (DLBCL) cells and sensitises DLBCL cells to rituximab. Br. J. Haematol. 2006, 134:475-484.
6. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-261.
7. Willis S.N., Chen L., Dewson G., Wei A., Naik E., Fletcher J.I., Adams J.M., Huang D.C. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes Dev. 2005, 19:1294-1305.
8. Akgul C. Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell. Mol. Life Sci. 2009, 66:1326-1336.
9. LoPiccolo J., Blumenthal G.M., Bernstein W.B., Dennis P.A. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist. Updates 2008, 11:32-50.
10. Chapuis N., Tamburini J., Green A.S., Vignon C., Bardet V., Neyret A., Pannetier M., Willems L., Park S., Macone A., Maira S.M., Ifrah N., Dreyfus F., Herault O., Lacombe C., Mayeux P., Bouscary D. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia. Clin. Cancer Res. 2010, 16:5424-5435.
11. Choo A.Y., Yoon S.O., Kim S.G., Roux P.P., Blenis J. Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation. Proc. Natl. Acad. Sci. USA 2008, 105:17414-17419.
12. Gupta M., Hendrickson A.E., Yun S.S., Han J.J., Schneider P.A., Koh B.D., Stenson M.J., Wellik L.E., Shing J.C., Peterson K.L., Flatten K.S., Hess A.D., Smith B.D., Karp J.E., Barr S., Witzig T.E., Kaufmann S.H. Dual mTORC1/mTORC2 inhibition diminishes Akt activation and induces Puma-dependent apoptosis in lymphoid malignancies. Blood 2011, 119:476-487.
13. Yang S., Xiao X., Meng X., Leslie K.K. A mechanism for synergy with combined mTOR and PI3 kinase inhibitors. PLoS One 2011, 6:e26343.
14. Harrington L.S., Findlay G.M., Lamb R.F. Restraining PI3K: mTOR signalling goes back to the membrane. Trends Biochem. Sci. 2005, 30:35-42.
15. O'Reilly K.E., Rojo F., She Q.B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. MTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
16. He X., Wang Y., Zhu J., Orloff M., Eng C. Resveratrol enhances the anti-tumor activity of the mTOR inhibitor rapamycin in multiple breast cancer cell lines mainly by suppressing rapamycin-induced AKT signaling. Cancer Lett. 2011, 301:168-176.
17. Sun S.Y., Rosenberg L.M., Wang X., Zhou Z., Yue P., Fu H., Khuri F.R. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. Cancer Res. 2005, 65:7052-7058.
18. Werzowa J., Cejka D., Fuereder T., Dekrout B., Thallinger C., Pehamberger H., Wacheck V., Pratscher B. Suppression of mTOR complex 2-dependent AKT phosphorylation in melanoma cells by combined treatment with rapamycin and LY294002. Br. J. Dermatol. 2009, 160:955-964.
19. Maira S.M., Stauffer F., Brueggen J., Furet P., Schnell C., Fritsch C., Brachmann S., Chene P., De Pover A., Schoemaker K., Fabbro D., Gabriel D., Simonen M., Murphy L., Finan P., Sellers W., Garcia-Echeverria C. Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol. Cancer Ther. 2008, 7:1851-1863.
20. Cho D.C., Cohen M.B., Panka D.J., Collins M., Ghebremichael M., Atkins M.B., Signoretti S., Mier J.W. The efficacy of the novel dual PI3-kinase/mTOR inhibitor NVP-BEZ235 compared with rapamycin in renal cell carcinoma. Clin. Cancer Res. 2010, 16:3628-3638.
21. Santiskulvong C., Konecny G.E., Fekete M., Chen K.Y., Karam A., Mulholland D., Eng C., Wu H., Song M., Dorigo O. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin. Cancer Res. 2011, 17:2373-2384.
22. Zang C., Liu H., Posch M.G., Waechter M., Facklam M., Fenner M.H., Ruthardt M., Possinger K., Phillip Koeffler H., Elstner E. Peroxisome proliferator-activated receptor gamma ligands induce growth inhibition and apoptosis of human B lymphocytic leukemia. Leuk. Res. 2004, 28:387-397.
23. Hsieh A.C., Liu Y., Edlind M.P., Ingolia N.T., Janes M.R., Sher A., Shi E.Y., Stumpf C.R., Christensen C., Bonham M.J., Wang S., Ren P., Martin M., Jessen K., Feldman M.E., Weissman J.S., Shokat K.M., Rommel C., Ruggero D. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012, 485:55-61.
24. Roccaro A.M., Sacco A., Husu E.N., Pitsillides C., Vesole S., Azab A.K., Azab F., Melhem M., Ngo H.T., Quang P., Maiso P., Runnels J., Liang M.C., Wong K.K., Lin C., Ghobrial I.M. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2012, 115:559-569.
25. Limon J.J., Fruman D.A. Akt and mTOR in B cell activation and differentiation. Front Immunol. 2012, 3:228.
26. Aziz S.A., Jilaveanu L.B., Zito C., Camp R.L., Rimm D.L., Conrad P., Kluger H.M. Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma. Clin. Cancer Res. 2010, 16:6029-6039.
27. Kang M.H., Reynolds C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res. 2009, 15:1126-1132.
28. Davis R.E., Brown K.D., Siebenlist U., Staudt L.M. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J. Exp. Med. 2001, 194:1861-1874.
29. Nawijn M.C., Alendar A., Berns A. For better or for worse: the role of Pim oncogenes in tumorigenesis. Nat. Rev. Cancer 2011, 11:23-34.
30. Fridberg M., Servin A., Anagnostaki L., Linderoth J., Berglund M., Soderberg O., Enblad G., Rosen A., Mustelin T., Jerkeman M., Persson J.L., Wingren A.G. Protein expression and cellular localization in two prognostic subgroups of diffuse large B-cell lymphoma: higher expression of ZAP70 and PKC-beta II in the non-germinal center group and poor survival in patients deficient in nuclear PTEN. Leuk. Lymphoma 2007, 48:2221-2232.
31. Kloo B., Nagel D., Pfeifer M., Grau M., Duwel M., Vincendeau M., Dorken B., Lenz P., Lenz G., Krappmann D. Critical role of PI3K signaling for NF-kappaB-dependent survival in a subset of activated B-cell-like diffuse large B-cell lymphoma cells. Proc. Natl. Acad. Sci. USA 2011, 108:272-277.
32. Uddin S., Hussain A.R., Siraj A.K., Manogaran P.S., Al-Jomah N.A., Moorji A., Atizado V., Al-Dayel F., Belgaumi A., El-Solh H., Ezzat A., Bavi P., Al-Kuraya K.S. Role of phosphatidylinositol 3'-kinase/AKT pathway in diffuse large B-cell lymphoma survival. Blood 2006, 108:4178-4186.
33. Smith S.M., van Besien K., Karrison T., Dancey J., McLaughlin P., Younes A., Smith S., Stiff P., Lester E., Modi S., Doyle L.A., Vokes E.E., Pro B. Temsirolimus has activity in non-mantle cell non-hodgkin's lymphoma subtypes: The University of Chicago Phase II Consortium. J. Clin. Oncol. 2010, (Epub ahead of print).
34. Majewski M., Korecka M., Kossev P., Li S., Goldman J., Moore J., Silberstein L.E., Nowell P.C., Schuler W., Shaw L.M., Wasik M.A. The immunosuppressive macrolide RAD inhibits growth of human Epstein-Barr virus-transformed B lymphocytes in vitro and in vivo: a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders. Proc. Natl. Acad. Sci. USA 2000, 97:4285-4290.
35. Witzig T.E., Reeder C.B., LaPlant B.R., Gupta M., Johnston P.B., Micallef I.N., Porrata L.F., Ansell S.M., Colgan J.P., Jacobsen E.D., Ghobrial I.M., Habermann T.M. A phase II trial of the oral mTOR inhibitor everolimus in relapsed aggressive lymphoma. Leukemia 2011, 25:341-347.
36. Yee K.W., Zeng Z., Konopleva M., Verstovsek S., Ravandi F., Ferrajoli A., Thomas D., Wierda W., Apostolidou E., Albitar M., O'Brien S., Andreeff M., Giles F.J. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies. Clin. Cancer Res. 2006, 12:5165-5173.
37. Baumann P., Mandl-Weber S., Oduncu F., Schmidmaier R. The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. Exp. Cell Res. 2009, 315:485-497.
38. Chiarini F., Grimaldi C., Ricci F., Tazzari P.L., Evangelisti C., Ognibene A., Battistelli M., Falcieri E., Melchionda F., Pession A., Pagliaro P., McCubrey J.A., Martelli A.M. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res. 2010, 70:8097-8107.
39. Bhende P.M., Park S.I., Lim M.S., Dittmer D.P., Damania B. The dual PI3K/mTOR inhibitor, NVP-BEZ235, is efficacious against follicular lymphoma. Leukemia 2010, 24:1781-1784.
40. Gomez-Abad C., Pisonero H., Blanco-Aparicio C., Roncador G., Gonzalez-Menchen A., Martinez-Climent J.A., Mata E., Rodriguez M.E., Munoz-Gonzalez G., Sanchez-Beato M., Leal J.F., Bischoff J.R., Piris M.A. PIM2 inhibition as a rational therapeutic approach in B-cell lymphoma. Blood 2011, 118:5517-5527.
41. Bianchini A., Loiarro M., Bielli P., Busa R., Paronetto M.P., Loreni F., Geremia R., Sette C. Phosphorylation of eIF4E by MNKs supports protein synthesis, cell cycle progression and proliferation in prostate cancer cells. Carcinogenesis 2008, 29:2279-2288.
42. Furic L., Rong L., Larsson O., Koumakpayi I.H., Yoshida K., Brueschke A., Petroulakis E., Robichaud N., Pollak M., Gaboury L.A., Pandolfi P.P., Saad F., Sonenberg N. EIF4E phosphorylation promotes tumorigenesis and is associated with prostate cancer progression. Proc. Natl. Acad. Sci. USA 2010, 107:14134-14139.
43. Lachance P.E., Miron M., Raught B., Sonenberg N., Lasko P. Phosphorylation of eukaryotic translation initiation factor 4E is critical for growth. Mol. Cell. Biol. 2002, 22:1656-1663.
44. Chen R., Chubb S., Cheng T., Hawtin R.E., Gandhi V., Plunkett W. Responses in mantle cell lymphoma cells to SNS-032 depend on the biological context of each cell line. Cancer Res. 2010, 70:6587-6597.